Doma Perpetual Exits 5% Stake in Pacira, Selling 2.9M Shares at $36.29 on Deal Announcement Day
PCRX sits 94% above its 52-week low of $18.8 on elevated volume (1.9× avg).
Summary
Doma Perpetual Capital Management and affiliates sold their entire 5%+ stake in Pacira BioSciences on the day the Viatris acquisition was announced, disposing of 2.9 million shares at $36.29 per share.
Key Events · Ownership and Investor Activity · PCRX
-
Doma Perpetual Exits 5% Stake
Doma Perpetual Capital Management and affiliates sold 2,936,784 shares at $36.29 per share on October 8, 2026, reducing their aggregate beneficial ownership to 0% and ceasing to be 5% owners.
-
Sale Coincides with Viatris Deal Announcement
The sales occurred on the same day Viatris announced its $36.50 per share all-cash acquisition of Pacira, with the sale price of $36.29 just below the deal price.
-
Transaction Breakdown
Doma Master Fund sold 1,965,765 shares, The John Templeton Foundation sold 812,019 shares, and Pedro Escudero sold 159,000 shares, plus 10 shares sold on October 13, 2026.
-
No Remaining Position
All reporting persons now report zero shares beneficially owned, representing a complete exit from the position.
Analysis · PCRX · Life Sciences
On October 8, 2026, the same day Viatris announced its $36.50 per share all-cash acquisition, Doma Perpetual Capital Management and affiliated entities sold their entire 5%+ position in Pacira BioSciences. The group disposed of 2,936,784 shares at $36.29 per share, just below the deal price, and now reports zero beneficial ownership. This complete exit by a significant institutional holder, executed at the acquisition announcement, removes a potential overhang and confirms the holder's decision to monetize rather than hold through closing.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCRX was trading at $36.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $18.80 to $36.46. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.